Vaccines, Blood & Biologics
Influenza Virus Vaccine for the 2006-2007 Season
Influenza Vaccine Lot Release Status
This chart provides information on flu vaccine lots that have been released by FDA. This information will be updated periodically as additional vaccine is received from manufacturers and released by FDA.
For information on flu vaccine distribution schedules, please contact the manufacturers directly.
Lots Released as of December 13, 2006
| Manufacturer | Total Number of Lots Released by FDA |
|---|---|
| Fluvirin Chiron Vaccines Ltd Gaskill Road Speke, Liverpool, L24 9GR, UK License 1720 |
48 |
| Fluarix GlaxoSmithKline Biologics Rue de l'Institut 89 B1330 Rixensart Belgium License 1617 |
31 |
| FluLaval ID Biomedical Corporation of Quebec (IDB) Sainte-Foy, Canada License 1739 |
38 |
| FluMist MedImmune Vaccines, Inc 297 North Bernardo Ave Mountain View, CA 94043 License 1652 |
21 |
| Fluzone Sanofi Pasteur, Inc Discovery Drive Swiftwater, PA 18370 License 1725 |
85 |
FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) met in Bethesda, Maryland, on February 17, 2006, to select the influenza virus strains for the composition of the influenza vaccine for use in the 2006-2007 U.S. influenza season. During this meeting, the advisory panel reviewed and evaluated the surveillance data related to epidemiology and antigenic characteristics, serological responses to 2005/2006 vaccines, and the availability of candidate strains and reagents.
The panel recommended that vaccines to be used in the 2006-2007 season in the U.S. contain the following:
- an A/New Caledonia/20/99 (H1N1)-like virus;
- an A/Wisconsin/67/2005 (H3N2)-like virus (A/Wisconsin/67/2005 and A/Hiroshima/52/2005strains);
- a B/Malaysia/2506/2004-like virus (B/Malaysia/2506/2004 and B/Ohio/1/2005 strains)
The influenza vaccine composition to be used in the 2006-2007 season in the U.S. is identical to that recommended by the World Health Organization on February 15, 2006.
